Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis

Molecular Therapy

Volumn 16, Issue 7, 2008, Pages 1243-1251

  Fernandes, Julio C ^a   Wang, Huijie ^a   Jreyssaty, Christian ^a   Benderdour, Mohamed ^a   Lavigne, Patrick ^a   Qiu, Xingpin ^a   Winnik, Francoise M ^a   Zhang, Xiaoling ^b,c,d   Dai, Kerong ^b,c,d   Shi, Qin ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; CHITOSAN; FOLIC ACID; FREUND ADJUVANT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; NAKED DNA; NANOPARTICLE; OSTEOCALCIN; PLASMID DNA; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE INJURY; BONE METABOLISM; BONE TURNOVER; CELL CULTURE; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCLAST; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE;

ANIMALIA; RATTUS;

EID: 45749097402     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.99     Document Type: Article

References (49)

1. Scott, DL (2000). Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 39 (suppl. 1): 24-29.
2. Abramson, SB and Amin, A (2002). Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 41: 972-980.
3. Bendele, AM, Chlipala, ES, Scherrer, J, Frazier, J, Sennello, G, Rich, WJ et al. (2000). Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 43: 2648-2659.
4. Evans, CH (2004). Gene therapies for osteoarthdtis. Curr Rheumatol Rep 6: 31-40.
5. Gouze, JN, Ghivizzani, SC, Gouze, E, Palmer, GD, Betz, OB, Robbins, PD et al. (2001). Gene therapy for rheumatoid arthritis. Hand Surg 6: 211-219.
6. Fernandes, J, Tardif, G, Martel-Pelletier, J, Lascau-Coman, V, Dupuis, M, Moldovan, F et al. (1999). In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: Prevention of osteoarthritis progression. Am J Pathol 154: 1159-1169.
7. Balicki, D, Putnam, CD, Scaria, PV and Beutler, E (2002). Structure and function correlation in histone H2A peptide-mediated gene transfer. Proc Natl Acad Sci USA 99: 7467-7471.
8. Cohen, H, Levy, RJ, Gao, J, Fishbein, I, Kousaev, V, Sosnowski, S et al. (2000). Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 7: 1896-1905.
9. Corsi, K, Chellat, F, Yahia, L and Fernandes, JC (2003). Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials 24: 1255-1264.
10. Borchard, G (2001). Chitosans for gene delivery. Adv Drug Deliv Rev 52: 145-150.
11. Li, XW, Lee, DK, Chan, AS and Alpar, HO (2003). Sustained expression in mammalian cells with DNA complexed with chitosan nanoparticles. Biochim Biophys Acta 1630: 7-18.
12. Godbey, WT, Wu, KK and Mikos, AG (1999). Size matters: Molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res 45: 268-275.
13. Lavertu, M, Methot, S, Tran-Khanh, N and Buschmann, MD (2006). High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 27: 4815-4824.
14. Sudimack, J and Lee, RJ (2000). Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41: 147-162.
15. Nakashima-Matsushita, N, Homma, T, Yu, S, Matsuda, T, Sunahara, N, Nakamura, T et al. (1999). Selective expression of folate receptor beta and it possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 42: 1609-1616.
16. Turk, MJ, Breur, GJ, Widmer, WR, Paulos, CM, Xu, LC, Grote, LA et al. (2002). Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum: 46: 1947-1955.
17. Mansouri, S, Cuie, Y, Winnik, F, Shi, Q, Lavigne, P, Benderdour, M et al. (2006). Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials 27: 2060-2065.
18. Lehman, MA, Kream, J and Brogna, D (1964). Acid and alkaline phosphatase activity in the serum and synovial fluid of patients with arthritis. J Bone Joint Surg Am 46: 1732-1738.
19. Lian, JB and Gundberg, CM (1988). Osteocalcin. Biochemical considerations and clinical applications. Clin Orthop Relat Res 226: 267-291.
20. Janckila, AJ, Neustadt, DH, Nakasato, YR, Halleen, JM, Hentunen, T and Yam, LT (2002). Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin Chim Acta 320: 49-58.
21. Romas, E, Bakharevski, O, Hards, DK, Kartsogiannis, V, Quinn, JM, Ryan, PF et al. (2000). Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 43: 821-826.
22. Gravallese, EM, Manning, C, Tsay, A, Naito, A, Pan, C, Armento, E et al. (2000). Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43: 250-258.
23. Fye, KH (1999). New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs. Postgrad Med 106: 82-90, 92.
24. Bendele, A (2001). Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact 1: 377-385.
25. O'Dell, JR (2004). Therapeutic strategies for rheumatoid arthritis. N Engl J Med 350: 2591-2602.
26. Bendele, A, McComb, J, Gould, T, McAbee, T, Sennello, G, Chlipala, E et al. (1999). Animal models of arthritis: Relevance to human disease. Toxicol Pathol 27: 134-142.
27. Woods, JM, Katschke, KJ, Volin, MV, Ruth, JH, Woodruff, DC, Amin, MA et al. (2001). IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol 166: 1214-1222.
28. Woods, JM, Amin, MA, Katschke, KJ Jr, Volin, MV, Ruth, JH, Connors, MA et al. (2002). Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis. Hum Gene Ther 13: 381-393.
29. Fernandes, JC, Martel-Pelletier, J and Pelletier, JP (2002). The role of cytokines in osteoarthritis pathophysiology. Biorheology 39: 237-246.
30. Kaneko, M, Tomita, T, Nakase, T, Ohsawa, Y, Seki, H, Takeuchi, E et al. (2001). Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis. Rheumotology (Oxford) 40: 247-255.
31. Wooley, PH, Whalen, JD, Chapman, DL, Berger, AE, Richard, KA, Aspar, DG et al. (1993). The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 36: 1305-1314.
32. Gowen, M, Wood, DD, Ihrie, EJ, McGuire, MK and Russell, RG (1983). An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306: 378-380.
33. Ramprasath, VR, Shanthi, P and Sachdanandam, P (2006). Curative effect of Semecarpus anacardium Linn. nut milk extract against adjuvant arthritis - with special reference to bone metabolism. Chem Biol Interact 160: 183-192.
34. Allen, MJ (2003). Biochemical markers of bone metabolism in animals: uses and limitations. Vet Clin Pathol 32: 101-113.
35. Tamura, T, Shirai, T, Kosaka, N, Ohmori, K and Takafumi, N (2002). Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur J Pharmacol 448: 81-87.
36. Fairney, A, Patel, KV, Hollings, NP and Seifert, MH (1990). Abnormal osteocalcin binding in rheumatoid arthritis. Ann Rheum Dis 49 229-230.
37. Price, PA, Williamson, MK and Lothringer, JW (1981). Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 256: 12760-12766.
38. Raisz, LG, Pilbeam, CC and Fall, PM (1993). Prostaglandins: Mechanisms of action and regulation of production in bone. Osteoporos Int 3 (suppl. 1): 136-140.
39. Faour, WH, He, Y, He, QW, de, LM, Quintero, M, Mancini, A et al. (2001). Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem 276: 31720-31731.
40. Burger, D, Dayer, JM, Palmer, G and Gabay, C (2006). Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 20: 879-896.
41. Feige, U, Hu, YL, Gasser, J, Campagnuolo, G, Munyakazi, L and Bolon, B (2000). Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 57: 1457-1470.
42. Paulos, CM, Varghese, B, Widmer, WR, Breur, GJ, Vlashi, E and Low, PS (2006). Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res Ther 8 R77.
43. Chandrasekar, D, Sistla, R, Ahmad, FJ, Khar, RK and Diwan, PV (2007). The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 28: 504-512.
44. Allan, GG and Peyron, M (1995). Molecular weight manipulation of chitosan. I: Kinetics of depolymerization by nitrous acid. Carbohydr Res 277: 257-272.
45. Mao, HQ, Roy, K, Troung-Le, VL, Janes, KA, Lin, KY, Wang, Y et al. (2001). Chitosan-DNA nanoparticles as gene carriers: Synthesis, characterization and transfection efficiency. J Control Release 70: 399-421.
46. Liu, F, Song, Y and Liu, D (1999). Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6 1258-1266.
47. Shi, Q, Vaillancourt, F, Cote, V, Fahmi, H, Lavigne, P, Afif, H et al. (2006). Alterations of metabolic activity in human osteoarthritic osteoblasts by lipid peroxidation end product 4-hydroxynonenal. Arthritis Res Ther 8:R159.
48. Smith, PK, Krohn, RI, Hermanson, GT, Mallia, AK, Gartner, FH, Provenzano, MD et al. (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85.
49. Parfitt, AM, Drezner, MK, Glorieux, FH, Kanis, JA, Malluche, H, Meunier, PJ et al. (1987). Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histophometry Nomenclature Committee. J Bone Miner Res 2: 595-610.